SCHEMBL24309685

SCHEMBL24309685

Cn1cc(S(=O)(=O)Nc2nc(Oc3ccccc3)cc(-c3ccccc3)n2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.47
▸ HTR1A P08908 4/20 0.45
▸ HTR7 P34969 4/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ TSHR P16473 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ GPR39 O43194 1/20 0.41
▸ CYP1A2 P05177 3/20 0.39
▸ CYP2C9 P11712 3/20 0.39
▸ CYP2C19 P33261 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ATM Q13315 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ BRD4 O60885 2/20 0.38
▸ EGFR P00533 2/20 0.37
▸ FGFR1 P11362 2/20 0.37
▸ KDR P35968 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26826527 0.89 HRH1 (0.42) MAPTHTR1AHTR7SMN1; SMN2ALDH1A1
SCHEMBL24310345 0.88 TSHR (0.43) MAPTHTR1AHTR7TSHRSMN1; SMN2
SCHEMBL29566612 0.88 TSHR (0.43) MAPTHTR1AHTR7TSHRSMN1; SMN2
SCHEMBL24309568 0.88 ALDH1A1 (0.47) MAPTMAPK1TDP1TSHRSMN1; SMN2
SCHEMBL26807460 0.87 HTR6 (0.43) MAPTHTR1AHTR7SMN1; SMN2
SCHEMBL24309624 0.87 TSHR (0.43) MAPTHTR1AHTR7TSHRSMN1; SMN2
SCHEMBL29566752 0.87 TSHR (0.43) MAPTHTR1AHTR7TSHRSMN1; SMN2
SCHEMBL26810050 0.86 HTR1A (0.42) MAPTHTR1AHTR7TSHRSMN1; SMN2
SCHEMBL29567073 0.85 HTR1A (0.43) MAPTHTR1AHTR7TSHRSMN1; SMN2
SCHEMBL24309659 0.85 HTR1A (0.43) MAPTHTR1AHTR7TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B MAPT 4864/4885HTR1A 4018/4885HTR7 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback